We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.12%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.4B
AUM Growth
-$236M
(-9%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-16.46%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
97
New
20
Increased
44
Reduced
26
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$85.4M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$45.1M |
| 3 |
Merck
MRK
|
+$36.1M |
| 4 |
Edwards Lifesciences
EW
|
+$21.1M |
| 5 |
CMRX
Chimerix, Inc.
CMRX
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$80.2M |
| 2 |
AGN
Allergan plc
AGN
|
+$63.6M |
| 3 |
Viatris
VTRS
|
+$58.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$54.9M |
| 5 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$48.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$29.7B
| $197M | 8.21% |
487,432
-10,780
| -2% | -$4.33M |
|
2
Gilead Sciences
GILD
$166B
| $153M | 6.37% |
1,304,407
-16,100
| -1% | -$1.76M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $146M | 6.07% |
1,257,558
+48,700
| +4% | +$5.57M |
|
|
4
BioMarin Pharmaceuticals
BMRN
$11.5B
| $132M | 5.51% |
965,877
-443,154
| -31% | -$54.9M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $119M | 4.96% |
657,525
+261,201
| +66% | +$45.1M |
|
6
Incyte
INCY
$23.1B
| $94.8M | 3.96% |
910,114
-426,030
| -32% | -$44.1M |
|
|
7
Regeneron Pharmaceuticals
REGN
$70.5B
| $89.2M | 3.72% |
+174,900
| New | +$85.4M |
|
8
Amgen
AMGN
$197B
| $87M | 3.63% |
566,497
-97,078
| -15% | -$15.6M |
|
9
Halozyme
HALO
$9.23B
| $78.5M | 3.27% |
3,477,051
-250,500
| -7% | -$4.4M |
|
10
Thermo Fisher Scientific
TMO
$196B
| $76.6M | 3.19% |
590,036
+2,900
| +0.5% | +$378K |
|
11
Vertex Pharmaceuticals
VRTX
$122B
| $73.9M | 3.08% |
598,800
+89,200
| +18% | +$11.2M |
|
|
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
| $70.8M | 2.95% |
5,004,322
+18,184
| +0.4% | +$219K |
|
13
Pfizer
PFE
$141B
| $61.3M | 2.56% |
1,927,279
+354,651
| +23% | +$11.6M |
|
|
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
| $61.1M | 2.55% |
1,262,075
+1,800
| +0.1% | +$74.3K |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $53.3M | 2.22% |
1,169,130
+6,400
| +0.6% | +$257K |
|
|
AGN
16
DELISTED
Allergan plc
AGN
| $48.9M | 2.04% |
161,031
-213,376
| -57% | -$63.6M |
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $42.9M | 1.79% |
177,647
+12,700
| +8% | +$3.38M |
|
|
TTPH
18
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $42.4M | 1.77% |
44,654
+14,384
| +48% | +$11.8M |
|
19
Medtronic
MDT
$107B
| $38.5M | 1.61% |
519,829
+111,703
| +27% | +$8.53M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
| $36.2M | 1.51% |
682,736
-389,701
| -36% | -$14.2M |
|
|
21
Merck
MRK
$309B
| $34.9M | 1.46% |
+643,306
| New | +$36.1M |
|
22
DexCom
DXCM
$29.4B
| $31.8M | 1.33% |
1,592,632
-5,600
| -0.4% | -$98.4K |
|
|
OMED
23
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $30.8M | 1.29% |
1,369,534
-164,044
| -11% | -$4.05M |
|
24
United Therapeutics
UTHR
$22.5B
| $30.6M | 1.28% |
175,780
+700
| +0.4% | +$126K |
|
25
Align Technology
ALGN
$12.5B
| $29.7M | 1.24% |
473,522
+40,382
| +9% | +$2.39M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sectoral Asset Management held 97 positions worth $2.4B, down 9% from $2.63B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sectoral Asset Management withdrew a net $395M in Q2 2015, closing 6 positions and reducing 26 holdings. Its most notable exit was Keryx Biopharmaceuticals Inc, an estimated $48.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Regeneron Pharmaceuticals worth $89.2M.
- Sectoral Asset Management's largest Q2 2015 buy was Regeneron Pharmaceuticals: 174,900 shares worth $89.2M.
- Sectoral Asset Management added most to Alexion Pharmaceuticals in Q2 2015, an estimated $45.1M increase.
- Sectoral Asset Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $80.2M.
- Sectoral Asset Management fully exited Keryx Biopharmaceuticals Inc in Q2 2015, selling an estimated $48.7M.
- Sectoral Asset Management's ten largest holdings make up 49% of its $2.4B portfolio in Q2 2015.
- Sectoral Asset Management opened 20 new positions and closed 6 in Q2 2015.
- Sectoral Asset Management's portfolio value fell 9% quarter-over-quarter to $2.4B.
Based on Sectoral Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.